Review
doi: 10.1016/j.iac.2006.02.004.
IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy
Affiliations
- PMID: 16701148
- DOI: 10.1016/j.iac.2006.02.004
Item in Clipboard
Review
IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy
Immunol Allergy Clin North Am.
2006 May.
Abstract
IgE-facilitated allergen presentation (FAP) is an important pathogenic mechanism in allergic disease and represents a potential therapeutic target. Allergen immunotherapy is a highly effective therapy, particularly in patients with seasonal pollinosis who fail to respond to usual pharmacotherapy. Allergen immunotherapy induces "blocking" IgG antibodies that are detectable in serum and have been shown to inhibit IgE-FAP in vitro. This review summarizes the main components involved in IgE-FAP and the potential value of a validated functional assay of serum inhibitory antibodies for IgE-FAP for monitoring the clinical response to immunotherapy.
Similar articles
-
A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation.Clin Exp Allergy. 2008 Aug;38(8):1290-301. doi: 10.1111/j.1365-2222.2008.03020.x. Epub 2008 May 28. Clin Exp Allergy. 2008. PMID: 18510696 Clinical Trial.
-
IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy.Int Arch Allergy Immunol. 2006;141(2):119-29. doi: 10.1159/000094714. Epub 2006 Jul 21. Int Arch Allergy Immunol. 2006. PMID: 16864979 Review.
-
Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation.J Immunol. 1999 Sep 1;163(5):2944-52. J Immunol. 1999. PMID: 10453043
-
Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses.Front Immunol. 2019 Jan 17;9:3131. doi: 10.3389/fimmu.2018.03131. eCollection 2018. Front Immunol. 2019. PMID: 30705676 Free PMC article. Review.
-
Allergen immunotherapy.Am Fam Physician. 2004 Aug 15;70(4):689-96. Am Fam Physician. 2004. PMID: 15338781 Review.
Cited by
-
Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction.Nat Commun. 2018 Jan 2;9(1):7. doi: 10.1038/s41467-017-02312-7. Nat Commun. 2018. PMID: 29295972 Free PMC article.
-
Patterns of Clinical Reactivity in a Danish Cohort of Tree Nut Allergic Children, Adolescents, and Young Adults.Front Allergy. 2022 Mar 28;3:824660. doi: 10.3389/falgy.2022.824660. eCollection 2022. Front Allergy. 2022. PMID: 35958942 Free PMC article.
-
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.J Allergy Clin Immunol. 2016 Apr;137(4):1103-1110.e11. doi: 10.1016/j.jaci.2015.10.005. Epub 2015 Nov 12. J Allergy Clin Immunol. 2016. PMID: 26581915 Free PMC article. Clinical Trial.
-
Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells.Cell Mol Immunol. 2016 May;13(3):391-400. doi: 10.1038/cmi.2015.19. Epub 2015 Mar 23. Cell Mol Immunol. 2016. PMID: 25942513 Free PMC article.
-
Clinical efficacy and immune regulation with peanut oral immunotherapy.J Allergy Clin Immunol. 2009 Aug;124(2):292-300, 300.e1-97. doi: 10.1016/j.jaci.2009.05.022. Epub 2009 Jul 3. J Allergy Clin Immunol. 2009. PMID: 19577283 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
